A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis

BJU International

Volumn 101, Issue 11, 2008, Pages 1448-1453

  Rouprêt, Morgan ^a,b,c   Hupertan, Vincent ^b   Yates, David R ^a   Comperat, Eva ^b   Catto, James W F ^a   Meuth, Mark ^a   Lackmichi, Amine ^b   Ricci, Sylvie ^b   Lacave, Roger ^b   Gattegno, Bernard ^b   Richard, François ^b   Hamdy, Freddie C ^a   Cussenot, Olivier ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Bayesian networks; DNA methylation; Loss of heterozygosity; Microsatellite analysis; Urinalysis; Urothelial cell carcinoma

Indexed keywords

BIOLOGICAL MARKER;

ACTBP2 GENE; ADULT; AGED; ARTICLE; BAYES THEOREM; BLOOD SAMPLING; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYSTOSCOPY; D9S162 GENE; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DNA METHYLATION; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; GENETIC MARKER; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IFNA GENE; MALE; MARKER GENE; MBP GENE; MICROSATELLITE MARKER; PRIORITY JOURNAL; PROMOTER REGION; RASSF1A GENE; URINARY TRACT CARCINOMA; VALIDATION PROCESS; WIF1 GENE;

AGED; AGED, 80 AND OVER; BAYES THEOREM; CARCINOMA, TRANSITIONAL CELL; DNA METHYLATION; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SENSITIVITY AND SPECIFICITY; URINALYSIS; URINARY BLADDER NEOPLASMS;

EID: 43049099377     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07591.x     Document Type: Article

References (31)

1. Chopin DK, Gattegno B. Superficial bladder tumors. Eur Urol 2002 42 : 533 41
2. Rabbani F, Perrotti M, Russo P, Herr HW. Upper-tract tumors after an initial diagnosis of bladder cancer: argument for long-term surveillance. J Clin Oncol 2001 19 : 94 100
3. Kirkali Z, Chan T, Manoharan M et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005 66 : 4 34
4. Enver MK, Miller PD, Chinegwundoh FI. Upper tract surveillance in primary bladder cancer follow-up. BJU Int 2004 94 : 790 2
5. Palou J, Rodriguez-Rubio F, Huguet J et al. Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. J Urol 2005 174 : 859 61
6. Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 2001 19 : 666 75
7. van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005 47 : 736 48
8. Wiener HG, Mian C, Haitel A, Pycha A, Schatzl G, Marberger M. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol 1998 159 : 1876 80
9. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003 21 : 1315 30
10. Karam JA, Lotan Y, Karakiewicz PI et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 2007 8 : 128 36
11. Catto JW, Azzouzi AR, Rehman I et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol 2005 23 : 2903 10
12. Amira N, Rivet J, Soliman H et al. Microsatellite instability in urothelial carcinoma of the upper urinary tract. J Urol 2003 170 : 1151 4
13. Catto JW, Azzouzi AR, Amira N et al. Distinct patterns of microsatellite instability are seen in tumours of the urinary tract. Oncogene 2003 22 : 8699 706
14. Friedrich MG, Weisenberger DJ, Cheng JC et al. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res 2004 10 : 7457 65
15. Amira N, Mourah S, Rozet F et al. Non-invasive molecular detection of bladder cancer recurrence. Int J Cancer 2002 101 : 293 7
16. Mourah S, Cussenot O, Vimont V et al. Assessment of microsatellite instability in urine in the detection of transitional-cell carcinoma of the bladder. Int J Cancer 1998 79 : 629 33
17. Schneider A, Borgnat S, Lang H et al. Evaluation of microsatellite analysis in urine sediment for diagnosis of bladder cancer. Cancer Res 2000 60 : 4617 22
18. Yates DR, Rehman I, Meuth M, Cross SS, Hamdy FC, Catto JW. Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls. Oncogene 2006 25 : 1984 8
19. Dhawan D, Hamdy FC, Rehman I et al. Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. J Pathol 2006 209 : 336 43
20. Maruyama R, Toyooka S, Toyooka KO et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 2001 61 : 8659 63
21. Abbod MF, Linkens DA, Catto JW, Hamdy FC. Comparative study of intelligent models for the prediction of bladder cancer progression. Oncol Rep 2006 15 (Special issue) : 1019 22
22. Finne P, Finne R, Stenman UH. Neural network analysis of clinicopathological factors in urological disease: a critical evaluation of available techniques. BJU Int 2001 88 : 825 31
23. Gevaert O, De Smet F, Timmerman D, Moreau Y, De Moor B. Predicting the prognosis of breast cancer by integrating clinical and microarray data with Bayesian networks. Bioinformatics 2006 22 : e184 90
24. Salzman P, Almudevar A. Using complexity for the estimation of Bayesian networks. Stat Appl Genet Mol Biol 2006 5 : Article 21
25. Bulashevska S, Szakacs O, Brors B, Eils R, Kovacs G. Pathways of urothelial cancer progression suggested by Bayesian network analysis of allelotyping data. Int J Cancer 2004 110 : 850 6
26. Hsia TC, Chiang HC, Chiang D, Hang LW, Tsai FJ, Chen WC. Prediction of survival in surgical unresectable lung cancer by artificial neural networks including genetic polymorphisms and clinical parameters. J Clin Lab Anal 2003 17 : 229 34
27. Bartoletti R, Cai T, Dal Canto M, Boddi V, Nesi G, Piazzini M. Multiplex polymerase chain reaction for microsatellite analysis of urine sediment cells: a rapid and inexpensive method for diagnosing and monitoring superficial transitional bladder cell carcinoma. J Urol 2006 175 : 2032 7
28. van Rhijn BW, Lurkin I, Kirkels WJ, van der Kwast TH, Zwarthoff EC. Microsatellite analysis - DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a phase II trial. Cancer 2001 92 : 768 75
29. Toyota M, Issa JP. CpG island methylator phenotypes in aging and cancer. Semin Cancer Biol 1999 9 : 349 57
30. van Rhijn BW, Lurkin I, Chopin DK et al. Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine. Clin Cancer Res 2003 9 : 257 63
31. Hoque MO, Topaloglu O, Begum S et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol 2005 23 : 6569 75